# Royalty Pharma plc (RPRX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Royalty Pharma plc's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/RPRX/mda/fy2025/): filed 2026-02-11; accession 0001802768-26-000003 (https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/RPRX/mda/fy2024/): filed 2025-02-12; accession 0001802768-25-000010 (https://www.sec.gov/Archives/edgar/data/1802768/000180276825000010/rprx-20241231.htm)
- [FY 2023 MD&A](/company/RPRX/mda/fy2023/): filed 2024-02-15; accession 0001802768-24-000012 (https://www.sec.gov/Archives/edgar/data/1802768/000180276824000012/rprx-20231231.htm)
- [FY 2022 MD&A](/company/RPRX/mda/fy2022/): filed 2023-02-15; accession 0001802768-23-000007 (https://www.sec.gov/Archives/edgar/data/1802768/000180276823000007/rprx-20221231.htm)
- [FY 2021 MD&A](/company/RPRX/mda/fy2021/): filed 2022-02-15; accession 0001802768-22-000011 (https://www.sec.gov/Archives/edgar/data/1802768/000180276822000011/rprx-20211231.htm)

Back to /company/RPRX/